skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%

Original Research

(6824) Views  (1287) Full article downloads

Authors: Seenu M Hariprasad, Levent Akduman, Joseph A Clever, Michael Ober, Franco M Recchia, et al

Published Date January 2009 Volume 2009:3 Pages 147 - 154
DOI: http://dx.doi.org/10.2147/OPTH.S4684

Seenu M Hariprasad1, Levent Akduman2, Joseph A Clever2, Michael Ober3,4, Franco M Recchia5, William F Mieler1,6

1Department of Ophthalmology and Visual Sciences, Vitreoretinal Service; 6Department of Ophthalmology and Visual Sciences, University of Chicago, Chicago, IL, USA; 2Vitreoretinal Service, Saint Louis University Eye Institute, Saint Louis, MO, USA; 3Vitreoretinal Service, Henry Ford Health Systems, West Bloomfield, MI, USA; 4Retinal Consultants of Michigan, Southfield, MI, USA; 5Vitreoretinal Service, Vanderbilt Eye Institute, Nashville, TN, USA

Purpose: To describe the use of nepafenac 0.1% for cystoid macular edema (CME).

Methods: This was a multicenter retrospective review of 22 CME cases (20 patients) treated with nepafenac 0.1% (six with concomitant prednisolone acetate 1%) from December 2005 to April 2008: three acute pseudophakic CME cases, 13 chronic/recalcitrant pseudophakic CME cases, and six cases of uveitic CME. Pre- and post-treatment retinal thickness and visual acuity were reported.

Results: Following treatment for six weeks to six months, six eyes with uveitic CME showed a mean retinal thickness improvement of 227 ± 168.1 μm; mean best-corrected visual acuity (BCVA) improvement was 0.36 ± 0.20 logMAR. All three cases of acute pseudophakic CME improved after four to 10 weeks of nepafenac, with a mean improvement in retinal thickness of 134 ± 111.0 μm. BCVA improved in two patients (0.16 and 0.22 logMAR) but not in the third due to underlying retinal pigment epithelium changes. Thirteen eyes with chronic/recalcitrant pseudophakic CME demonstrated a mean improvement in retinal thickness of 178 ± 128.7 μm after nepafenac and mean BCVA improvement of 0.33 ± 0.19 logMAR.

Conclusion: The positive outcomes of these 22 eyes strongly suggest that nepafenac 0.1% is a promising drug for the treatment of CME. Additional study under randomized controlled conditions is warranted.

Keywords: macular edema, NSAID, nepafenac, cataract surgery, uveitis








Readers of this article also read:

Acquired color vision and visual field defects in patients with ocular hypertension and early glaucoma
Bevacizumab (Avastin®) for the management of anterior chamber neovascularization and neovascular glaucoma
Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives
Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine
Insight into 144 patients with ocular vascular events during VEGF antagonist injections
Lamellar macular hole formation following vitrectomy for rhegmatogenous retinal detachment repair
Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination
Cytomegalovirus retinitis after central retinal vein occlusion in a patient on systemic immunosuppression: does venooclusive disease predispose to cytomegalovirus retinitis in patients already at risk?